This segment focuses on the research, development, and commercialization of fully human monoclonal antibodies (mAbs) to treat life-threatening infections. Aridis utilizes proprietary technologies to discover and develop mAbs targeting various bacterial and viral pathogens. R&D activities include antibody discovery, preclinical studies, and clinical trials. The company's lead product candidate, AR-301, is in Phase III trials for *S. aureus* lung infections. Other programs target *P. aeruginosa*, respiratory syncytial virus (RSV), and *Acinetobacter baumannii*. The patient impact is significant, as these therapies address unmet medical needs in treating antibiotic-resistant infections and viral diseases. Market positioning involves targeting add-on treatments to standard-of-care antibiotics. Future opportunities include expanding the pipeline to address additional pathogens and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for clinical development and commercialization.

This segment is dedicated to the development of antibody-based therapies for the treatment of COVID-19. Aridis is developing AR-712 and AR-701, a cocktail of two fully human IgG1 mAbs, currently in Phase I/II clinical trials for mild to moderate non-hospitalized COVID-19 patients. The research and development activities include antibody discovery, preclinical studies, and clinical trials to evaluate the safety and efficacy of these therapies. The therapeutic area focuses on addressing the ongoing need for effective treatments against the SARS-CoV-2 virus. The patient impact is aimed at reducing the severity of COVID-19 symptoms and preventing hospitalization in early-stage patients. Market positioning involves providing an alternative treatment option for COVID-19, potentially as an add-on therapy. Future opportunities include expanding the use of these therapies to treat different variants of the virus and exploring combination therapies. Regulatory and clinical aspects involve navigating the regulatory approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for clinical development and commercialization.

This segment focuses on the development of anti-infective therapies for chronic lung infections in cystic fibrosis (CF) patients. Aridis is developing AR-501, an anti-infective therapy, currently in Phase I/IIa clinical trials to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The research and development activities include the discovery and development of novel therapies to combat the chronic lung infections associated with CF. The therapeutic area focuses on improving the quality of life for CF patients by addressing the underlying infections that contribute to lung damage and respiratory complications. The patient impact is aimed at reducing the frequency and severity of lung infections, improving lung function, and potentially extending the lifespan of CF patients. Market positioning involves providing a targeted therapy to address a significant unmet medical need in the CF community. Future opportunities include expanding the pipeline to address additional pathogens and exploring combination therapies. Regulatory and clinical aspects involve navigating the regulatory approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for clinical development and commercialization.